Microsaic Systems plc New compact screening platform (1595S)
12 Novembro 2021 - 4:00AM
UK Regulatory
TIDMMSYS
RNS Number : 1595S
Microsaic Systems plc
12 November 2021
Microsaic Systems plc
("Microsaic" or the "Company")
New compact screening platform for human and environmental
health
Microsaic (AIM: MSYS) announces the addition of a new technology
capability to its platform, as part of the strategic transition
from equipment only sales to remote detection and analysis of human
diagnostics and environmental health monitoring. This latest
addition to the platform is expected to launch in H1 2022.
Mass Spectrometry ("MS") is often considered the gold standard
analytical technique for laboratory-based diagnosis. Microsaic's
compact technology allows for MS analysis at the point of need,
providing the unique capability to detect a large range of chemical
entities in Human Diagnostics and Environmental Monitoring.
The latest addition to Microsaic's platform is the integration
of the Company's compact MS technology with Gas Chromatography
("GC") and extends Microsaic's existing applications in Liquid
Chromatography ("LC"). This combination will provide an extensive
range of analysis required by end-users for chemical detection, for
use in a combined market estimated to be worth over $1Bn*.
Microsaic's platform now offers automated detection of organic
chemicals in both non-volatile and volatile compounds such as
therapeutics, antibiotics, pesticides, petrochemicals, and personal
care products. The platform can be used in Human Diagnostics where
measurements are increasingly being made in the doctor's clinic or
during surgery, with applications including the real time
monitoring of Therapeutic Drugs. Microsaic's technologies can also
detect contaminants in soil and water in minutes and is well suited
to front line environmental monitoring of chemicals of emerging
concern ("CEC") at the point of need.
Glenn Tracey, CEO of Microsaic, commented:
"Our enhanced platform will provide us with a significant
opportunity for screening in both Human Health and Environmental
applications."
"This transition to a data-centric and commercially focused
company, strategically positions us at the core of addressing many
global societal problems. Together, these advanced technologies and
partnerships in Human and Environmental Health, established this
year are expected to completely transform our business in 2022
."
Environmental legislation:
The COP26 Summit is a reminder that legislation is being drafted
in all key economies to address climate change aimed at protection
against soil and water contamination. Critical to this, is the
understanding of factors affecting the ecosystem so that mitigation
can take place immediately and cataclysmic damage to the
environment can be prevented. There is now clear demand for green,
sustainable, and ecological technology, to serve real-time
environmental monitoring and, at the same time, deliver "lab
performance" on the front line. Microsaic's platform has been
designed to satisfy that need perfectly.
Digital Health Care Revolution:
Additionally, trends towards delocalised health care continue,
where diagnosis, treatment and monitoring are happening in the
doctor's clinic, or during surgery itself. Microsaic's MCSP creates
high-fidelity data in real-time, and provides insights and allows
decisions to be made without delay and without the need for
time-consuming referrals to specialists or A&E.
*SDI Report
Enquiries:
Microsaic Systems plc
Glenn Tracey, CEO - Bevan Metcalf,
FD +44 (0)1483 751 577
Singer Capital Markets
(Nominated Adviser & Joint Broker) +44 (0)20 7496 3000
Aubrey Powell / George Tzimas (Investment
Banking)
Turner Pope Investments (TPI) Limited
(Joint Broker)
Andy Thacker / James Pope +44 (0) 20 3657 0050
About Microsaic ( www.microsaic.com )
Microsaic listed on AIM in 2011 to develop and commercialise
micro-engineering chip-based mass spectrometry equipment. Having
invested GBP30m over the last 20 years before and after the IPO,
Microsaic has a robust patent portfolio in cutting-edge technology
purpose built for "Industry 4.0" which enables analytical detection
and characterisation at the point-of-need, whether within a human
health environment, conventional laboratory setting, or within a
bioprocessing facility for continuous mass spectrometer detection
and monitoring of data at any step in the process workflow.
Microsaic's products and systems are commercially available
through global markets via a network of regional and local
partners, targeting its core laboratory, manufacturing, and
point-of-need applications.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCZZMMMGMDGMZZ
(END) Dow Jones Newswires
November 12, 2021 02:00 ET (07:00 GMT)
Microsaic Systems (LSE:MSYS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Microsaic Systems (LSE:MSYS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024